Repligen Corp (RGEN)

$151.12 +1.75 (1.17%)
Market Cap 8.41B
Revenue (ttm) 634.44M
Net Income (ttm) -25.51M
EPS (ttm) N/A
PE Ratio 94.20
Forward PE 75.86
Profit Margin -4.02%
Debt to Equity Ratio 0.00
Volume 592,100
Avg Vol 635,746
Day's Range N/A - N/A
Shares Out 56.29M
Stochastic %K 15%
Beta 1.12
Analysts Strong Sell
Price Target $188.59

Company Profile

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale co...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 781 250 0111
Fax: 781 250 0115
Address:
Building 1, Suite 100 41 Seyon Street, Waltham, United States
SuperGreenToday
SuperGreenToday Jan. 29 at 4:44 PM
$RGEN Share Price: $154.66 Contract Selected: Jun 18, 2026 $155 Calls Buy Zone: $13.94 – $17.22 Target Zone: $22.98 – $28.08 Potential Upside: 56% ROI Time to Expiration: 139 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Estimize
Estimize Jan. 19 at 12:03 PM
Wall St is expecting 0.44 EPS for $RGEN Q4 [Reporting 02/25 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 6 at 4:28 PM
$RGEN RSI: 72.29, MACD: 2.5962 Vol: 4.18, MA20: 163.33, MA50: 159.25 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
KaleKing
KaleKing Dec. 25 at 9:35 AM
$RGEN Risk premia compress only when proof accumulates, because growth without leverage now attracts skepticism. A coherent operating roadmap would be catalytic.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 8:53 AM
$RGEN RSI: 49.84, MACD: 1.8184 Vol: 4.18, MA20: 163.42, MA50: 157.68 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ortega1963
ortega1963 Dec. 22 at 4:11 PM
$RGEN
0 · Reply
ortega1963
ortega1963 Dec. 22 at 4:07 PM
$RGEN long 166
0 · Reply
Mal1ah_Bowen
Mal1ah_Bowen Dec. 16 at 4:54 PM
$RGEN SBFM this one doesn’t need hype, it just needs attention
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 9:07 PM
Barclays has updated their rating for Repligen ( $RGEN ) to Overweight with a price target of 200.
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 6:29 PM
Wells Fargo updates rating for Repligen ( $RGEN ) to Overweight, target set at 175 → 190.
0 · Reply
Latest News on RGEN
Conestoga Mid Cap Composite Q4 2025 Leaders And Laggards

Jan 25, 2026, 10:09 AM EST - 8 days ago

Conestoga Mid Cap Composite Q4 2025 Leaders And Laggards

BSY CSGP GNRC IDXX JKHY POOL ROL

Repligen Corporation (RGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 2:55 AM EST - 20 days ago

Repligen Corporation (RGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair

Jan 6, 2026, 7:30 AM EST - 4 weeks ago

Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair

Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference

Dec 18, 2025, 7:30 AM EST - 6 weeks ago

Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference

Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows

Dec 16, 2025, 7:30 AM EST - 7 weeks ago

Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows

Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 4:43 PM EST - 2 months ago

Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Repligen Corporation to Present at Evercore Healthcare Conference

Nov 26, 2025, 7:30 AM EST - 2 months ago

Repligen Corporation to Present at Evercore Healthcare Conference

Repligen Corporation (RGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 18, 2025, 2:48 PM EST - 2 months ago

Repligen Corporation (RGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Repligen Corporation (RGEN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 18, 2025, 11:18 AM EST - 2 months ago

Repligen Corporation (RGEN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Repligen: Rare Growth In The Biopharma Supplies Industry

Nov 14, 2025, 3:28 AM EST - 2 months ago

Repligen: Rare Growth In The Biopharma Supplies Industry

Repligen Corporation (RGEN) Presents at Stifel 2025 Healthcare Conference Transcript

Nov 11, 2025, 3:11 PM EST - 2 months ago

Repligen Corporation (RGEN) Presents at Stifel 2025 Healthcare Conference Transcript

Repligen Corporation (RGEN) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 1:41 PM EST - 3 months ago

Repligen Corporation (RGEN) Presents at UBS Global Healthcare Conference 2025 Transcript

Repligen Corporation (RGEN) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 5:01 PM EDT - 3 months ago

Repligen Corporation (RGEN) Q3 2025 Earnings Call Transcript

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Oct 28, 2025, 7:30 AM EDT - 3 months ago

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Repligen to Report Third Quarter 2025 Financial Results

Oct 15, 2025, 7:30 AM EDT - 3 months ago

Repligen to Report Third Quarter 2025 Financial Results

Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 25, 2025, 11:37 AM EDT - 4 months ago

Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Repligen Corporation (RGEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 4, 2025, 10:32 AM EDT - 5 months ago

Repligen Corporation (RGEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 5 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN IONS MRNA

Repligen Corporation to Present at Upcoming September Conferences

Aug 22, 2025, 7:30 AM EDT - 5 months ago

Repligen Corporation to Present at Upcoming September Conferences

Repligen Corporation: Still Navigating Through The Covid Cliff

Aug 14, 2025, 3:24 PM EDT - 6 months ago

Repligen Corporation: Still Navigating Through The Covid Cliff

Repligen Stock Outlook: Risk Skewed To The Downside Through 2026

Jul 31, 2025, 10:45 AM EDT - 6 months ago

Repligen Stock Outlook: Risk Skewed To The Downside Through 2026

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

Jul 31, 2025, 7:30 AM EDT - 6 months ago

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 5:31 PM EDT - 6 months ago

Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript

Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Jul 29, 2025, 7:30 AM EDT - 6 months ago

Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Repligen to Report Second Quarter 2025 Financial Results

Jul 17, 2025, 7:30 AM EDT - 7 months ago

Repligen to Report Second Quarter 2025 Financial Results

908 Devices Appoints Christopher D. Brown to its Board of Directors

Jun 16, 2025, 8:00 AM EDT - 8 months ago

908 Devices Appoints Christopher D. Brown to its Board of Directors

MASS

Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report

May 27, 2025, 7:30 AM EDT - 9 months ago

Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report

Repligen Corporation to Present at Upcoming May Investor Conferences

May 7, 2025, 7:30 AM EDT - 9 months ago

Repligen Corporation to Present at Upcoming May Investor Conferences

Repligen Corporation (RGEN) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 12:58 PM EDT - 9 months ago

Repligen Corporation (RGEN) Q1 2025 Earnings Call Transcript

Repligen Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:30 AM EDT - 10 months ago

Repligen Reports First Quarter 2025 Financial Results

Repligen Appoints Jacob Johnson As Vice President Investor Relations

Apr 8, 2025, 7:30 AM EDT - 10 months ago

Repligen Appoints Jacob Johnson As Vice President Investor Relations

Repligen: Ongoing Bioprocessing Market Recovery

Mar 20, 2025, 7:52 AM EDT - 11 months ago

Repligen: Ongoing Bioprocessing Market Recovery

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

Mar 4, 2025, 1:26 PM EST - 11 months ago

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

MASS

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

Mar 4, 2025, 7:30 AM EST - 1 year ago

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

MASS

Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 2:53 PM EST - 1 year ago

Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

Feb 20, 2025, 2:00 PM EST - 1 year ago

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 11, 2025, 7:30 AM EST - 1 year ago

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:30 AM EST - 1 year ago

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Repligen Launches the CTech™ SoloVPE® PLUS System

Jan 6, 2025, 7:30 AM EST - 1 year ago

Repligen Launches the CTech™ SoloVPE® PLUS System

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

Dec 16, 2024, 8:11 AM EST - 1 year ago

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

BLFS

Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report

Dec 12, 2024, 7:30 AM EST - 1 year ago

Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report

Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

Dec 9, 2024, 7:30 AM EST - 1 year ago

Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 3:07 PM EST - 1 year ago

Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript

Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth

Nov 12, 2024, 1:19 PM EST - 1 year ago

Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth

Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects

Nov 12, 2024, 6:36 AM EST - 1 year ago

Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects

Repligen Corporation to Present at Upcoming Investor Conferences

Nov 5, 2024, 7:30 AM EST - 1 year ago

Repligen Corporation to Present at Upcoming Investor Conferences

Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More

Oct 14, 2024, 11:15 AM EDT - 1 year ago

Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More

Repligen Opens Training & Innovation Center to Elevate Customer Experience

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Repligen Opens Training & Innovation Center to Elevate Customer Experience

Repligen Corporation to Present at Wells Fargo Healthcare Conference

Aug 23, 2024, 7:30 AM EDT - 1 year ago

Repligen Corporation to Present at Wells Fargo Healthcare Conference

Exclusive: Repligen in bid for reagent vendor Maravai, sources say

Aug 16, 2024, 11:46 AM EDT - 1 year ago

Exclusive: Repligen in bid for reagent vendor Maravai, sources say

MRVI

SuperGreenToday
SuperGreenToday Jan. 29 at 4:44 PM
$RGEN Share Price: $154.66 Contract Selected: Jun 18, 2026 $155 Calls Buy Zone: $13.94 – $17.22 Target Zone: $22.98 – $28.08 Potential Upside: 56% ROI Time to Expiration: 139 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Estimize
Estimize Jan. 19 at 12:03 PM
Wall St is expecting 0.44 EPS for $RGEN Q4 [Reporting 02/25 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 6 at 4:28 PM
$RGEN RSI: 72.29, MACD: 2.5962 Vol: 4.18, MA20: 163.33, MA50: 159.25 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
KaleKing
KaleKing Dec. 25 at 9:35 AM
$RGEN Risk premia compress only when proof accumulates, because growth without leverage now attracts skepticism. A coherent operating roadmap would be catalytic.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 8:53 AM
$RGEN RSI: 49.84, MACD: 1.8184 Vol: 4.18, MA20: 163.42, MA50: 157.68 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ortega1963
ortega1963 Dec. 22 at 4:11 PM
$RGEN
0 · Reply
ortega1963
ortega1963 Dec. 22 at 4:07 PM
$RGEN long 166
0 · Reply
Mal1ah_Bowen
Mal1ah_Bowen Dec. 16 at 4:54 PM
$RGEN SBFM this one doesn’t need hype, it just needs attention
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 9:07 PM
Barclays has updated their rating for Repligen ( $RGEN ) to Overweight with a price target of 200.
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 6:29 PM
Wells Fargo updates rating for Repligen ( $RGEN ) to Overweight, target set at 175 → 190.
0 · Reply
Goldenpoint9
Goldenpoint9 Dec. 15 at 1:48 PM
$RGEN
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 4 at 2:46 PM
$RGEN Current Stock Price: $163.60 Contracts to trade: $165 RGEN Dec 19 2025 Call Entry: $5.62 Exit: $9.99 ROI: 78% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Estimize
Estimize Nov. 27 at 11:00 AM
Wall St is expecting 0.44 EPS for $RGEN Q4 [Reporting 02/25 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co
0 · Reply
c2rshi2r
c2rshi2r Nov. 26 at 7:50 PM
$RGEN https://www.marketbeat.com/instant-alerts/rep-lisa-c-mcclain-sells-repligen-corporation-nasdaqrgen-stock-2025-11-25/
0 · Reply
stockpicker63
stockpicker63 Nov. 21 at 3:25 PM
Watch today $RGEN, $VFC and $INTU
0 · Reply
ZacksResearch
ZacksResearch Oct. 29 at 5:19 PM
$RGEN beats earnings — but the stock drops anyway. Revenue surged year over year and Q3 results topped estimates, yet shares slid as tighter EPS guidance cooled the bullish momentum. Full breakdown here 👉 https://www.zacks.com/stock/news/2780407/rgens-q3-earnings-beat-estimates-revenues-surge-yy-stock-down?cid=sm-stocktwits-2-2780407-teaser-18313&ADID=SYND_STOCKTWITS_TWEET_2_2780407_TEASER_18313
0 · Reply
ZacksResearch
ZacksResearch Oct. 29 at 3:56 PM
$RGEN beats Q3 earnings but shares drop 5.9%! 🤔 Despite surpassing the Zacks Consensus Estimate with 46 cents per share and a 22% year-over-year revenue spike, concerns over tighter EPS guidance might have dampened investor sentiment. 📉 Check out the full analysis here 👉 https://www.zacks.com/stock/news/2780407/rgens-q3-earnings-beat-estimates-revenues-surge-yy-stock-down?cid=sm-stocktwits-2-2780407-body-18257&ADID=SYND_STOCKTWITS_TWEET_2_2780407_BODY_18257
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 28 at 12:16 PM
$RGEN
0 · Reply